Wednesday, December 2, 2015

Senate Report Criticizes Gilead's Pricing Strategy for Sovaldi Bloomberg BNA-2 hours ago The current backlog of ANDAs at the FDA is compounding the problem of price spikes, the group said. Since the Generic

Senate Report Criticizes Gilead's Pricing Strategy for Sovaldi

Bloomberg BNA-2 hours ago
The current backlog of ANDAs at the FDA is compounding the problem of price spikes, the group said. Since the Generic

No comments: